Susquehanna International Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
Sell
-30,900
Closed -$6K 11085
2018
Q1
$6K Sell
30,900
-36,400
-54% -$33.6K ﹤0.01% 9197
2017
Q4
$87K Sell
67,300
-15,500
-19% -$25.2K ﹤0.01% 8745
2017
Q3
$176K Buy
82,800
+1,600
+2% +$3.9K ﹤0.01% 8109
2017
Q2
$235K Sell
81,200
-35,700
-31% -$107K ﹤0.01% 8023
2017
Q1
$402K Buy
116,900
+60,900
+109% +$240K ﹤0.01% 6878
2016
Q4
$97K Sell
56,000
-85,800
-61% -$202K ﹤0.01% 9100
2016
Q3
$471K Buy
141,800
+129,760
+1,078% +$490K ﹤0.01% 6163
2016
Q2
$52K Sell
12,040
-5,810
-33% -$26.3K ﹤0.01% 8230
2016
Q1
$100K Buy
17,850
+270
+2% +$3.51K ﹤0.01% 8432
2015
Q4
$302K Sell
17,580
-3,490
-17% -$83.2K ﹤0.01% 7679
2015
Q3
$445K Buy
21,070
+2,560
+14% +$87.7K ﹤0.01% 7343
2015
Q2
$916K Sell
18,510
-47,310
-72% -$2.83M ﹤0.01% 6402
2015
Q1
$5.15M Sell
65,820
-6,980
-10% -$433K ﹤0.01% 2698
2014
Q4
$4.41M Sell
72,800
-44,120
-38% -$2.22M ﹤0.01% 3079
2014
Q3
$4.98M Buy
116,920
+22,060
+23% +$1.18M ﹤0.01% 3024
2014
Q2
$5.86M Buy
94,860
+8,610
+10% +$501K ﹤0.01% 2827
2014
Q1
$5.61M Buy
86,250
+25,840
+43% +$1.75M ﹤0.01% 2731
2013
Q4
$3.4M Buy
60,410
+2,760
+5% +$155K ﹤0.01% 3482
2013
Q3
$3.54M Sell
57,650
-10,220
-15% -$692K ﹤0.01% 3228
2013
Q2
$3.97M Buy
+67,870
New +$4.18M ﹤0.01% 2921

Other funds holding OREX

Susquehanna International Group's OREX Position: Q2 2018 in Review

Susquehanna International Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 88,896 shares — an estimated $18K sold.

Susquehanna International Group first reported a position in OREX in Q2 2013 and held it in 20 quarters. The position peaked at $7.16M in Q2 2014. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

  • Susquehanna International Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Susquehanna International Group sold 88,896 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $18K.
  • Susquehanna International Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
  • Susquehanna International Group's Orexigen Therapeutics, Inc. position peaked at $7.16M in Q2 2014.
  • 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.